6505--RSV Vaccine

PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue Request for Proposal (RFP) #36E79725R0043 for an unrestricted procurement for the Respiratory Syncytial Virus Vaccine (RSV Vaccine) for the Department of Veterans Affairs (VA) and Option 2 State Veterans Homes (SVH)), Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC).

VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s and DoD s respective Pharmaceutical Prime Vendor Programs.

Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC number that is unique to the offeror. Solicitation #36E79725R0043 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about June 2, 2025, with a tentative closing date of June 16, 2025. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at SAM.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check Contracting Opportunities at SAM.gov for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Deb Fassl. Questions can be e-mailed to Deborah.Fassl@va.gov or Nicholas.McGregor@va.gov.

The estimated annual requirements are as follows:

REQUIREMENT DESCRIPTION

ITEM

DESCRIPTION

PKG SIZE

(Kit/Syringe/Vial)

TOTAL ESTIMATED ANNUAL USAGE

(Vials)

1

RSV Vaccine

1

248,803

The RSV Vaccine national contract will be a mandatory source, unless the awarded product is not clinically appropriate. The awarded national contract product will not be a mandatory source when not clinically appropriate, such as for patients outside the age range covered by the awarded contract product s indications.

Offerors must propose all presentations and package sizes offered commercially. All alternative presentations/package sizes must be proposed at the same price per dose.